Navigation Links
China's Type 2 Diabetes Drug Market Will More than Triple by 2012

New Entries to China Drug Market to Garner More Than $270 Million in

Combined Sales, According to a New Report by Decision Resources

WALTHAM, Mass., May 28 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, forecasts that the Chinese type 2 diabetes drug market will more than triple by 2012. According to the new Emerging Markets report entitled Type 2 Diabetes in China, this growth will be fueled by increased access to health insurance, greater patient spending power and more aggressive treatment practice, leading to increased usage of newer agents such as the insulin analogues. Additionally, the number of prevalent cases of type 2 diabetes in China is among the highest in the world -- 62.5 million cases in 2007 -- a number that rivals that of the United States, Europe and Japan combined (48.5 million cases). The high prevalence rate in China reflects an aging population and urbanization-associated risk factors, such as diet and lack of physical activities.

"The Chinese government and medical associations are promoting guidelines published by the American Diabetes Association, the World Health Organization and the Chinese Society of Diabetes," said Victor Li, Ph.D., analyst at Decision Resources. "All guidelines advocate earlier and more-aggressive interventions in type 2 diabetes patients. We forecast that the patient population treated with polypharmacy will nearly double between 2007 and 2012."

The report also finds that three new type 2 diabetes agents with novel mechanisms -- Eli Lilly/Amylin's Byetta, Merck's Januvia and Novartis's Galvus -- are expected to launch in China by 2012. The combined sales of these three agents will surpass $270 million by 2012. However, the high cost of many antidiabetic therapies, particularly Western-branded drugs, is a major barrier to effective management of type 2 diabetes in China. Patient ability to pay for medications influences physician prescribing habits, particularly prescription of newer drugs such as the peroxisome proliferator-activated receptor (PPAR)-gamma agonists and the insulin analogues, which are not reimbursed or are only partially reimbursed in some provinces.

About Emerging Markets - China

Emerging Markets - China is the first and only syndicated report series focusing on high-growth emerging markets with comprehensive disease-specific analysis. With these reports, biopharmaceutical companies can accomplish the following:

-- More accurately assess the commercial opportunity for Western brands in

key pharmaceutical markets of China -- Beijing, Shanghai,

Guangzhou -- and in the high-growth second-tier markets of Tianjin,

Wuhan, Nanjing, Hangzhou, and Jinan.

-- Understand the physician treatment patterns and drivers of choice in

key first- and second-tier cities based on primary research.

-- Gain a clear perspective of the Chinese five-year market forecast at

the drug level, broken out by urban and rural areas, and by sales from

multinational and Chinese-based companies.

About Decision Resources

Decision Resources, Inc. ( is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Elizabeth Marshall

Decision Resources, Inc.


SOURCE Decision Resources, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Perot Systems and ChinaSoft to Pursue Chinese Healthcare Opportunities
2. New insights in diagnosing diabetes may help the millions who are undiagnosed
3. Rhinestone Cure Sets the Glitz to Benefit Diabetes at Hotel Indigo
4. New Antioxidant Drug Shows Promise Against Diabetes
5. Lifestyle Changes Can Keep Diabetes at Bay for 14 Years
6. Anti-rejection drug may increase risk of diabetes after kidney transplant
7. Study: Doctors not always sure when to treat BP in people with diabetes
8. Study: Doctors Not Always Sure When to Treat Blood Pressure in People With Diabetes
9. Seattle Laces Up To Beat the Bridge and Diabetes
10. Data from Pooled Analyses Demonstrates Welchol, Combined with Metformin- or Sulfonylurea-Based Therapy, Significantly Lowers Blood Glucose in Adults with Type 2 Diabetes
11. American Diabetes Wholesale Launches Affiliate Program
Post Your Comments:
(Date:11/24/2015)... IN (PRWEB) , ... November 24, 2015 , ... ... benefits advisory organization, is pleased to welcome Winter-Dent & Company as its newest ... from day one to become a client's most trusted advisor regardless of whether ...
(Date:11/24/2015)... ... November 24, 2015 , ... Serenity Point Rehabilitation, a ... of recent video interviews with some of the staff members at their recovery center. ... treatment facility, as well as some of the things that make their recovery program ...
(Date:11/24/2015)... ... November 24, 2015 , ... Abington Hospital ... Aetna Institute of Quality® Bariatric Surgery Facility for treating individuals living with morbid ... health care services available to its members to help them make informed decisions ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... and Healthy Aging Program have announced their endorsement of the Medical Fitness ... Health Fitness is proud to have the MFN as one of our endorsed ...
(Date:11/24/2015)... ... November 24, 2015 , ... World Patent ... Blending, a household invention that revolutionizes the vending machine industry by providing healthy ... is worth $2 billion," says Scott Cooper, CEO and Creative Director of World ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... 24, 2015  DILON Diagnostics and GE Healthcare are ... for DILON to distribute GE,s Discovery NM750b Molecular Breast ... of this distribution agreement will provide Dilon,s experienced distribution ... system and is considered an initial step in an ... for clinicians and their patients. --> ...
(Date:11/24/2015)... COMMACK, N.Y. , Nov. 24, 2015 ... Pacemaker System, is pleased to announce the appointment of ... ... and pediatric cardiology at Children,s Hospital, Uppsala University, Uppsala ... . From 1984-1986, he was a fellow at the ...
(Date:11/24/2015)... BERN, Switzerland , November 24, 2015 ... for Biomedical Engineering Research of the University of ... Endocrinology, Diabetes and Clinical Nutrition of the Bern University ... an exclusive collaboration to develop a novel generation artificial ... personalised delivery of insulin for diabetic patients with the ...
Breaking Medicine Technology: